Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05074303 · ClinicalTrials.gov registry record · Phase 2

Beta-glucan and Immune Response to Influenza Vaccine

A Phase 2 study of Healthy Aging, sponsored by University of Florida.

Completed
Registry status
Phase 2
Development phase
78
Enrollment target
1
Study location

NCT05074303 is a Phase 2 study of Healthy Aging that has completed, run by University of Florida. The registered enrollment target is 78 participants, below the 119-participant average among 40 other Healthy Aging trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05074303, a Phase 2 study of Healthy Aging, has completed, sponsored by University of Florida.

COMPLETED
Registry status
Phase 2
Development phase
78 participants
Enrollment target
1
Study location

Study Summary

This trial in healthy adults will determine the effects of beta-glucan, a dietary fiber supplement isolated from baker's yeast, on immune response to the influenza vaccine.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Beta-glucan
  • BIOLOGICAL Influenza Vaccine

Study Locations (1)

Florida

  • Food Science and Human Nutrition Department, University of Florida - Gainesville

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2022-07-18
Est. Completion 2024-08-28
Phase Phase 2

Sponsor

University of Florida

1,106 total trials

What the Registry Record Tells You About NCT05074303

The ClinicalTrials.gov registry entry for NCT05074303 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 40 other Healthy Aging trials with a reported enrollment target (34% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Aging appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT05074303 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05074303 about?

NCT05074303 is a clinical study titled "Beta-glucan and Immune Response to Influenza Vaccine". This trial in healthy adults will determine the effects of beta-glucan, a dietary fiber supplement isolated from baker's yeast, on immune response to the influenza vaccine.

What is the current status of trial NCT05074303?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2022-07-18. Estimated completion is 2024-08-28.

What conditions does trial NCT05074303 study?

This clinical trial studies the following conditions: Healthy Aging.

What interventions are being tested in trial NCT05074303?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Beta-glucan (DIETARY_SUPPLEMENT), Influenza Vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT05074303?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05074303 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Aging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.